Reported 1 day ago
Investors are eagerly awaiting results from Amgen’s mid-stage trial of its weight-loss drug, MariTide, as it could challenge established GLP-1 medications. Preliminary findings have already boosted Amgen’s stock, but concerns over safety and necessary weight loss percentages persist. Analysts suggest that a successful trial could significantly elevate shares, while disappointing results could lead to declines.
Source: YAHOO